Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
Executive Summary
While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.
You may also be interested in...
Scrip 100 Analysis: Impairment, Youth Boost R&D Spending
Spending on R&D increased substantially in 2016; but the picture is complicated and more than half of the increase is due to accountancy updates following drug program failures, one large company's commitment to new projects, and young companies fuelled by generous financial markets.
No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie
Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.
With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field
J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise. In February, Merck lowered sales expectations for its investigational "nuc" MK-3682.